应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
BMY 施贵宝
已收盘 10-21 16:00:00 EDT
52.12
-1.10
-2.07%
盘后
52.19
+0.07
+0.13%
19:59 EDT
最高
53.30
最低
52.10
成交量
535.29万
今开
53.28
昨收
53.22
日振幅
2.25%
总市值
1,057亿
流通市值
1,055亿
总股本
20.27亿
成交额
2.81亿
换手率
0.26%
流通股本
20.24亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
百时美施贵宝上涨1.22%，报53.405美元/股
金融界 · 10-17
百时美施贵宝上涨1.22%，报53.405美元/股
百时美施贵宝上涨1.22%，报53.31美元/股
金融界 · 10-15
百时美施贵宝上涨1.22%，报53.31美元/股
百时美施贵宝(BMY.US)纳武利尤单抗联合伊匹木单抗疗法在华获批
智通财经 · 10-14
百时美施贵宝(BMY.US)纳武利尤单抗联合伊匹木单抗疗法在华获批
韦格威生产商诺和诺德在印度大力投资人才和人工智能合作伙伴关系
Reuters · 10-11
韦格威生产商诺和诺德在印度大力投资人才和人工智能合作伙伴关系
更新版 2-辉瑞与 Starboard 之争白热化，对冲基金称高管施压
路透中文 · 10-10
更新版 2-辉瑞与 Starboard 之争白热化，对冲基金称高管施压
百时美施贵宝下跌1.21%，报52.795美元/股
金融界 · 10-09
百时美施贵宝下跌1.21%，报52.795美元/股
百时美施贵宝(BMY.US)与Prime Medicine(PRME.US)合作开发创新细胞疗法
智通财经 · 10-03
百时美施贵宝(BMY.US)与Prime Medicine(PRME.US)合作开发创新细胞疗法
百时美施贵宝上涨3.01%，报54.49美元/股
金融界 · 10-02
百时美施贵宝上涨3.01%，报54.49美元/股
百时美施贵宝上涨1.26%，报52.39美元/股
金融界 · 10-01
百时美施贵宝上涨1.26%，报52.39美元/股
百时美施贵宝击败因抗癌药延期上市而提起的 64 亿美元诉讼
Reuters · 10-01
百时美施贵宝击败因抗癌药延期上市而提起的 64 亿美元诉讼
Prime Medicine大涨约45% 与施贵宝签署研究合作与许可协议
港股那点事 · 09-30
Prime Medicine大涨约45% 与施贵宝签署研究合作与许可协议
BUZZ-由于获得百时美施贵宝的投资和许可协议，Prime Medicine 将迎来有史以来最好的一天
路透中文 · 09-30
BUZZ-由于获得百时美施贵宝的投资和许可协议，Prime Medicine 将迎来有史以来最好的一天
BUZZ-在获得百时美施贵宝投资和达成许可协议后，Prime Medicine 公司业绩上升
Reuters · 09-30
BUZZ-在获得百时美施贵宝投资和达成许可协议后，Prime Medicine 公司业绩上升
百利天恒BL-B01D1获临床研究新进展 合作方百时美施贵宝积极推进产品全球临床开发
每日经济新闻 · 09-29
百利天恒BL-B01D1获临床研究新进展 合作方百时美施贵宝积极推进产品全球临床开发
美国股票-通胀报告温和提振小型股，道指创下历史新高
Reuters · 09-28
美国股票-通胀报告温和提振小型股，道指创下历史新高
精神分裂新疗法药物获批，美国”医药巨头“百时美施贵宝涨1.6%！
华尔街见闻 · 09-27
精神分裂新疗法药物获批，美国”医药巨头“百时美施贵宝涨1.6%！
BUZZ--美国股票走势-木薯科学公司、波浪生命科学公司、班布尔公司
Reuters · 09-27
BUZZ--美国股票走势-木薯科学公司、波浪生命科学公司、班布尔公司
百时美施贵宝(BMY.US)重磅抗精神病药物获批 带动股价盘前大涨
智通财经网 · 09-27
百时美施贵宝(BMY.US)重磅抗精神病药物获批 带动股价盘前大涨
BUZZ-券商观点布里斯托尔公司的抗精神病药物未被警告是一个重大利好消息
Reuters · 09-27
BUZZ-券商观点布里斯托尔公司的抗精神病药物未被警告是一个重大利好消息
BUZZ--美国股票走势-Bumble、Cassava Sciences、IonQ
Reuters · 09-27
BUZZ--美国股票走势-Bumble、Cassava Sciences、IonQ
加载更多
公司概况
公司名称：
施贵宝
所属市场：
NYSE
上市日期：
--
主营业务：
百时美施贵宝公司于1933年8月根据特拉华州法律注册成立，名为百时美公司，继承了1887年在纽约成立的一家企业。1989年，由于合并，公司更名为百时美施贵宝公司。公司在全球范围内从事生物制药产品的发现、开发、许可、制造、营销、分销和销售。他们在全球范围内从事生物制药产品的发现、开发、许可、制造、营销、分销和销售。 他们预计他们对Celgene和MyoKardia的收购将进一步将他们定位为领先的生物制药公司，通过多项近期资产和额外的外部合作伙伴扩大他们的肿瘤学、血液学、免疫学和心血管产品组合。
发行价格：
--
{"stockData":{"symbol":"BMY","market":"US","secType":"STK","nameCN":"施贵宝","latestPrice":52.12,"timestamp":1729540800000,"preClose":53.22,"halted":0,"volume":5352891,"hourTrading":{"tag":"盘后","latestPrice":52.19,"preClose":52.12,"latestTime":"19:59 EDT","volume":210319,"amount":10963285.6893,"timestamp":1729555172141},"delay":0,"floatShares":2023702885,"shares":2027395178,"eps":-3.218878,"marketStatus":"已收盘","marketStatusCode":5,"change":-1.1,"latestTime":"10-21 16:00:00 EDT","open":53.28,"high":53.3,"low":52.1,"amount":280553956.63797003,"amplitude":0.022548,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.218878,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1729584000000},"adr":0,"listingDate":-18475200000,"adjPreClose":53.22,"adrRate":0,"dividendRate":0.045472,"preHourTrading":{"tag":"盘前","latestPrice":53.1,"preClose":53.22,"latestTime":"09:14 EDT","volume":1863,"amount":98901.93052800001,"timestamp":1729516449441},"postHourTrading":{"tag":"盘后","latestPrice":52.19,"preClose":52.12,"latestTime":"19:59 EDT","volume":210319,"amount":10963285.6893,"timestamp":1729555172141},"volumeRatio":0.665329,"optionData":{"bulkOrders":[{"symbol":"BMY","call":false,"expireDate":1731646800000,"strike":"45.0","timestamp":1729522773455,"price":0.14000000059604645,"volume":3595,"amount":50330,"type":"+"},{"symbol":"BMY","call":true,"expireDate":1731646800000,"strike":"45.0","timestamp":1729522773455,"price":7.809999942779541,"volume":3595,"amount":2807695,"type":"-"}]},"impliedVol":0.359,"impliedVolPercentile":0.9641},"requestUrl":"/m/hq/s/BMY","defaultTab":"news","newsList":[{"id":"2476946289","title":"百时美施贵宝上涨1.22%，报53.405美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2476946289","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476946289?lang=zh_cn&edition=full","pubTime":"2024-10-17 00:20","pubTimestamp":1729095647,"startTime":"0","endTime":"0","summary":"10月17日，百时美施贵宝(BMY)盘中上涨1.22%，截至00:20，报53.405美元/股，成交1.31亿美元。财务数据显示，截至2024年06月30日，百时美施贵宝收入总额240.66亿美元，同比增长6.66%；归母净利润-102.31亿美元，同比减少336.01%。大事提醒：10月31日，百时美施贵宝将于(美东)盘前披露2024财年三季报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/10/17002044085913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU1093756325.SGD","LU1670710661.SGD","BK4588","LU1670711123.USD","LU0306807586.USD","IE00B2B36J28.USD","LU1670710588.SGD","LU0321505868.SGD","LU2242646821.SGD","IE0009355771.USD","BK4581","LU2360032135.SGD","BK4007","BK4534","LU1670711040.USD","LU0225284248.USD","IE00BSNM7G36.USD","LU1718418525.SGD","IE00BJT1NW94.SGD","LU2125154935.USD","LU2242652126.USD","IE0002141913.USD","BMY","LU1585245621.USD","LU0306806265.USD","IE00BFTCPJ56.SGD","LU0114720955.EUR","LU1032466523.USD","LU0061475181.USD","LU1093756168.USD","LU2133065610.SGD","BK4585","LU0868494617.USD","LU1074936037.SGD","LU0321505439.SGD","LU0985481810.HKD","LU2125154778.USD","LU0456855351.SGD","LU0225771236.USD","BK4559","LU1291159041.SGD","LU1571399168.USD","LU1989771016.USD","BK4532","LU1261432733.SGD","LU0882574055.USD","LU1430594728.SGD","LU0237698245.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2475680473","title":"百时美施贵宝上涨1.22%，报53.31美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2475680473","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475680473?lang=zh_cn&edition=full","pubTime":"2024-10-15 22:38","pubTimestamp":1729003095,"startTime":"0","endTime":"0","summary":"10月15日，百时美施贵宝(BMY)盘中上涨1.22%，截至22:38，报53.31美元/股，成交1.79亿美元。财务数据显示，截至2024年06月30日，百时美施贵宝收入总额240.66亿美元，同比增长6.66%；归母净利润-102.31亿美元，同比减少336.01%。大事提醒：10月31日，百时美施贵宝将于(美东)盘前披露2024财年三季报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/10/15223844036943.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4007","LU1093756168.USD","BK4559","LU0456855351.SGD","LU2133065610.SGD","LU1585245621.USD","IE00BFTCPJ56.SGD","LU0306807586.USD","LU1430594728.SGD","IE00B2B36J28.USD","IE00BSNM7G36.USD","LU0114720955.EUR","LU0225284248.USD","BK4532","LU1032466523.USD","IE0009355771.USD","LU2242646821.SGD","BMY","LU2360032135.SGD","BK4534","IE00BJT1NW94.SGD","LU0321505439.SGD","IE00BJJMRZ35.SGD","LU1718418525.SGD","LU2125154935.USD","BK4585","LU0237698245.USD","LU1571399168.USD","BK4588","LU2242652126.USD","LU0061475181.USD","LU1670711040.USD","LU1989771016.USD","LU1670710661.SGD","BK4581","LU0868494617.USD","IE0002141913.USD","LU1074936037.SGD","LU1093756325.SGD","LU1291159041.SGD","LU0306806265.USD","LU0321505868.SGD","LU1670711123.USD","LU1670710588.SGD","LU2125154778.USD","LU1261432733.SGD","LU0225771236.USD","LU0985481810.HKD","LU0882574055.USD"],"gpt_icon":0},{"id":"2475638402","title":"百时美施贵宝(BMY.US)纳武利尤单抗联合伊匹木单抗疗法在华获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2475638402","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475638402?lang=zh_cn&edition=full","pubTime":"2024-10-14 13:43","pubTimestamp":1728884580,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，10月14日，百时美施贵宝宣布其“双免疫联合疗法”纳武利尤单抗联合伊匹木单抗的上市申请已获得中国国家药监局批准，用于一线治疗不可切除或转移性微卫星高度不稳定性或错配修复缺陷型结直肠癌患者。这也正是该联合疗法本次获批的适应症。根据百时美施贵宝消息，本次获批是基于CheckMate-8HW研究结果。约830名患者被随机分配至纳武利尤单抗单药治疗组、纳武利尤单抗联合伊匹木单抗治疗组或研究者选择的化疗方案组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1193273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0306806265.USD","BK4007","LU1430594728.SGD","BK4532","LU1718418525.SGD","LU0306807586.USD","LU1291159041.SGD","LU1670710588.SGD","LU0225284248.USD","BK4588","IE0009355771.USD","BK4581","IE00B2B36J28.USD","LU0114720955.EUR","LU1093756168.USD","LU1074936037.SGD","LU1093756325.SGD","LU0061475181.USD","BK4559","LU0868494617.USD","LU1989771016.USD","LU1670711123.USD","LU1670710661.SGD","BMY","LU0321505868.SGD","IE0002141913.USD","LU0321505439.SGD","LU1261432733.SGD","IE00BJT1NW94.SGD","LU0225771236.USD","LU1032466523.USD","IE00BFTCPJ56.SGD","LU2125154935.USD","LU2360032135.SGD","LU0456855351.SGD","LU0985481810.HKD","LU2125154778.USD","LU2133065610.SGD","LU0237698245.USD","BK4585","LU2242652126.USD","BK4534","IE00BSNM7G36.USD","LU1670711040.USD","LU1571399168.USD","IE00BJJMRZ35.SGD","LU0882574055.USD","LU1585245621.USD","LU2242646821.SGD"],"gpt_icon":0},{"id":"2474236065","title":"韦格威生产商诺和诺德在印度大力投资人才和人工智能合作伙伴关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2474236065","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474236065?lang=zh_cn&edition=full","pubTime":"2024-10-11 18:00","pubTimestamp":1728640808,"startTime":"0","endTime":"0","summary":"道伯说，诺和诺德还与印度的10家初创公司建立了合作关系，利用人工智能完成一系列任务，包括总结文件、提取见解和检查编辑错误。押宝印度诺和诺德并不是唯一一家在印度押下重注的大型制药公司。诺和诺德全球安全评估工作的一半由其印度业务部门负责，该部门负责跟踪药物副作用报告并与全球卫生监管机构分享。诺和诺德没有对扩大印度中心或其人工智能合作伙伴关系的投资金额发表评论，但确认它愿意与印度更多的此类初创企业合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","IE00BJJMRZ35.SGD","LU0256863811.USD","LU1061106388.HKD","LU0471298694.HKD","LU1585245621.USD","LU1093756325.SGD","LU0096364046.USD","LU0868494617.USD","LU1571399168.USD","LU1074936037.SGD","LU0114720955.EUR","BMY","IE0002141913.USD","LU0122379950.USD","LU1023059063.AUD","IE00BJT1NW94.SGD","LU0321505868.SGD","BK4534","LU0289739699.SGD","BK4533","LU0708995401.HKD","LU0237698245.USD","IE0004445239.USD","IE00BJLML261.HKD","LU1057294990.SGD","LU1989771016.USD","BK4559","LU0109391861.USD","LU0061475181.USD","LU0006306889.USD","LU0058720904.USD","LU0354030511.USD","BK4007","IE00B1BXHZ80.USD","LU1261432733.SGD","LU1035775433.USD","LU0225771236.USD","LU1093756168.USD","LLY","LU0354030438.USD","NVO","LU0094547139.USD","LU0985481810.HKD","LU0225284248.USD","LU0943347566.SGD","LU0079474960.USD","LU2242652126.USD","GB00BDT5M118.USD","LU0882574055.USD"],"gpt_icon":0},{"id":"2474726399","title":"更新版 2-辉瑞与 Starboard 之争白热化，对冲基金称高管施压","url":"https://stock-news.laohu8.com/highlight/detail?id=2474726399","media":"路透中文","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474726399?lang=zh_cn&edition=full","pubTime":"2024-10-10 21:18","pubTimestamp":1728566286,"startTime":"0","endTime":"0","summary":"更新版 2-辉瑞与 Starboard 之争白热化，对冲基金称高管施压新版通篇介绍竞选活动、信件、会议、股价和辉瑞历史的细节Svea Herbst-Bayliss/Michael Erman. 路透10月10日 - 周四，辉瑞PFE.N与Starboard Value之间的企业冲突升温，在两名前高管退出针对辉瑞的竞选活动后，这家激进投资公司要求这家美国制药商调查其董事会的行为。Starboard 声称，前高管之所以反悔，是因为辉瑞内部人员或其代表联系了雷德和达梅利奥，\"据称威胁要对他们提起代价高昂的诉讼\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241010:nL4T3LM126:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","LU0122379950.USD","BK4592","IE00BFTCPJ56.SGD","LU0306807586.USD","LU1430594728.SGD","IE00B2B36J28.USD","IE00BSNM7G36.USD","LU0114720955.EUR","LU0225284248.USD","IE00BLSP4452.SGD","BK4532","SG9999002232.USD","SG9999001176.SGD","BMY","SG9999003800.SGD","LU2360032135.SGD","IE0002270589.USD","SG9999013999.USD","LU0321505439.SGD","LU1894683348.USD","SG9999011175.SGD","IE00BJJMRZ35.SGD","LU1718418525.SGD","SG9999002224.SGD","LU2125154935.USD","LU0170899867.USD","BK4568","LU0237698245.USD","LU2242652126.USD","IE00BLSP4239.USD","LU0234572021.USD","LU1989771016.USD","LU1670710661.SGD","BK4581","IE000M9KFDE8.USD","IE0002141913.USD","LU0058720904.USD","PFE","LU1894683264.USD","LU1066051498.USD","LU0321505868.SGD","BK4533","LU1670711123.USD","LU1670710588.SGD","LU2125154778.USD","SGXZ57979304.SGD","SG9999001176.USD","LU0289739699.SGD","LU1032466523.USD"],"gpt_icon":1},{"id":"2474408684","title":"百时美施贵宝下跌1.21%，报52.795美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2474408684","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474408684?lang=zh_cn&edition=full","pubTime":"2024-10-09 00:07","pubTimestamp":1728403652,"startTime":"0","endTime":"0","summary":"10月9日，百时美施贵宝(BMY)盘中下跌1.21%，截至00:07，报52.795美元/股，成交1.27亿美元。财务数据显示，截至2024年06月30日，百时美施贵宝收入总额240.66亿美元，同比增长6.66%；归母净利润-102.31亿美元，同比减少336.01%。大事提醒：10月7日，百时美施贵宝获巴克莱上调目标价至43美元，最新评级Underweight。10月31日，百时美施贵宝将于(美东)盘前披露2024财年三季报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/10/09000743797405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["IE00BJJMRZ35.SGD","LU1585245621.USD","LU1670711040.USD","LU1093756325.SGD","LU1670710661.SGD","LU0868494617.USD","LU1571399168.USD","LU1074936037.SGD","BK4585","LU2125154778.USD","LU0306807586.USD","LU0114720955.EUR","BMY","LU2133065610.SGD","BK4532","IE0002141913.USD","LU0306806265.USD","IE00BJT1NW94.SGD","LU1291159041.SGD","LU0321505868.SGD","IE00BSNM7G36.USD","BK4534","LU1718418525.SGD","LU0237698245.USD","LU1989771016.USD","LU1430594728.SGD","LU1032466523.USD","BK4559","LU2125154935.USD","LU2360032135.SGD","LU0061475181.USD","BK4007","LU1261432733.SGD","IE00BFTCPJ56.SGD","LU0456855351.SGD","LU1093756168.USD","LU1670710588.SGD","BK4588","LU0321505439.SGD","LU1670711123.USD","LU0985481810.HKD","IE00B2B36J28.USD","LU0225284248.USD","LU2242646821.SGD","BK4581","LU2242652126.USD","IE0009355771.USD","LU0225771236.USD","LU0882574055.USD"],"gpt_icon":0},{"id":"2472840396","title":"百时美施贵宝(BMY.US)与Prime Medicine(PRME.US)合作开发创新细胞疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2472840396","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472840396?lang=zh_cn&edition=full","pubTime":"2024-10-03 08:09","pubTimestamp":1727914147,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，9月30日，Prime Medicine宣布与施贵宝达成战略研发合作和授权协议，共同开发下一代T细胞疗法。这一合作将结合Prime Medicine精准的多重基因编辑能力，及施贵宝在开发和商业化创新细胞疗法方面的专长。根据协议，Prime Medicine将对选定的特定靶点设计优化的Prime Editor，并使用其PASSIGE技术平台。Prime Medicine的技术将Prime Editing与整合酶或其他位点特异性重组酶相结合，将大基因货物引入基因组，以实现稳定的货物表达。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1189870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B2B36J28.USD","LU2360032135.SGD","LU1430594728.SGD","BK4139","LU0225771236.USD","PRME","IE00BSNM7G36.USD","LU0321505439.SGD","BK4588","LU1093756325.SGD","LU0237698245.USD","LU1670710661.SGD","LU1571399168.USD","LU0868494617.USD","LU0985481810.HKD","IE0002141913.USD","LU1670711123.USD","LU1093756168.USD","LU1291159041.SGD","LU0306807586.USD","LU2133065610.SGD","BMY","LU0061475181.USD","LU0114720955.EUR","IE0009355771.USD","LU0225284248.USD","LU1074936037.SGD","IE00BJJMRZ35.SGD","LU1989771016.USD","BK4007","IE00BFTCPJ56.SGD","LU2125154778.USD","BK4532","LU0321505868.SGD","LU0882574055.USD","BK4585","LU1032466523.USD","LU1670710588.SGD","IE00BJT1NW94.SGD","LU1670711040.USD","LU0456855351.SGD","LU1718418525.SGD","LU2125154935.USD","BK4559","LU1261432733.SGD","LU1585245621.USD","LU2242646821.SGD","BK4581","BK4534","LU2242652126.USD"],"gpt_icon":0},{"id":"2472573937","title":"百时美施贵宝上涨3.01%，报54.49美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2472573937","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472573937?lang=zh_cn&edition=full","pubTime":"2024-10-02 23:42","pubTimestamp":1727883754,"startTime":"0","endTime":"0","summary":"10月2日，百时美施贵宝(BMY)盘中上涨3.01%，截至23:42，报54.49美元/股，成交4.18亿美元。财务数据显示，截至2024年06月30日，百时美施贵宝收入总额240.66亿美元，同比增长6.66%；归母净利润-102.31亿美元，同比减少336.01%。大事提醒：10月31日，百时美施贵宝将于(美东)盘前披露2024财年三季报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/10/02234243713186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0061475181.USD","LU1571399168.USD","LU1670710588.SGD","IE00B2B36J28.USD","LU1261432733.SGD","LU1989771016.USD","LU1718418525.SGD","IE00BFTCPJ56.SGD","LU1093756168.USD","IE00BJT1NW94.SGD","LU0882574055.USD","LU1670711123.USD","LU2133065610.SGD","LU1670710661.SGD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0306806265.USD","LU2242652126.USD","BK4588","LU0868494617.USD","BK4581","LU1430594728.SGD","LU0321505439.SGD","IE00BSNM7G36.USD","LU0306807586.USD","BK4534","BK4559","LU1032466523.USD","LU0225771236.USD","LU1670711040.USD","LU1291159041.SGD","LU2125154935.USD","LU2242646821.SGD","LU2360032135.SGD","LU0985481810.HKD","IE0009355771.USD","LU1585245621.USD","LU1093756325.SGD","LU1074936037.SGD","LU0114720955.EUR","LU0237698245.USD","LU0321505868.SGD","LU0225284248.USD","LU2125154778.USD","BMY","BK4532","BK4585","BK4007","LU0456855351.SGD"],"gpt_icon":0},{"id":"2472637744","title":"百时美施贵宝上涨1.26%，报52.39美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2472637744","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472637744?lang=zh_cn&edition=full","pubTime":"2024-10-01 22:53","pubTimestamp":1727794381,"startTime":"0","endTime":"0","summary":"10月1日，百时美施贵宝(BMY)盘中上涨1.26%，截至22:53，报52.39美元/股，成交1.71亿美元。财务数据显示，截至2024年06月30日，百时美施贵宝收入总额240.66亿美元，同比增长6.66%；归母净利润-102.31亿美元，同比减少336.01%。大事提醒：10月31日，百时美施贵宝将于(美东)盘前披露2024财年三季报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/10/01225343703786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0321505439.SGD","LU1430594728.SGD","LU1585245621.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0985481810.HKD","LU0306807586.USD","LU0456855351.SGD","IE00BJJMRZ35.SGD","LU2125154778.USD","LU0882574055.USD","LU1989771016.USD","BK4581","BK4007","IE0009355771.USD","LU1291159041.SGD","LU1093756168.USD","LU0225771236.USD","LU2242652126.USD","LU2360032135.SGD","LU1032466523.USD","LU0061475181.USD","BK4534","LU2125154935.USD","BK4532","LU2133065610.SGD","LU0868494617.USD","LU1093756325.SGD","LU1261432733.SGD","LU1670711040.USD","LU1670711123.USD","LU1074936037.SGD","LU0225284248.USD","LU1670710588.SGD","BK4585","IE0002141913.USD","LU0237698245.USD","LU0306806265.USD","LU1670710661.SGD","LU0321505868.SGD","LU1571399168.USD","LU1718418525.SGD","LU0114720955.EUR","BK4588","IE00BSNM7G36.USD","LU2242646821.SGD","BMY","BK4559"],"gpt_icon":0},{"id":"2472334373","title":"百时美施贵宝击败因抗癌药延期上市而提起的 64 亿美元诉讼","url":"https://stock-news.laohu8.com/highlight/detail?id=2472334373","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472334373?lang=zh_cn&edition=full","pubTime":"2024-10-01 01:39","pubTimestamp":1727717967,"startTime":"0","endTime":"0","summary":"百时美施贵宝公司及其律师也没有立即回应类似请求。CVR 持有者指责百时美施贵宝公司在向 FDA 提交关键信息和准备工厂接受检查方面行动迟缓，希望借此推迟审批，避免 64 亿美元的赔偿。百时美施贵宝于 2021 年 2 月 5 日获得 FDA 批准生产 Breyanzi，用于治疗非霍奇金淋巴瘤。该案名为 UMB Bank NA 诉百时美施贵宝公司，美国地区法院，纽约南区，第 21-04897 号。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","BMY","LU1291159041.SGD","LU1670710588.SGD","IE0002141913.USD","BK4007","LU0237698245.USD","LU0306807586.USD","LU0321505439.SGD","LU0321505868.SGD","LU0985481810.HKD","LU2125154778.USD","LU0456855351.SGD","LU2242652126.USD","LU2360032135.SGD","LU1585245621.USD","LU1430594728.SGD","IE00BFTCPJ56.SGD","LU0882574055.USD","LU1261432733.SGD","LU1571399168.USD","LU1718418525.SGD","LU2242646821.SGD","IE00BJJMRZ35.SGD","LU1670711040.USD","BK4585","IE00B2B36J28.USD","LU2133065610.SGD","LU1032466523.USD","BK4581","LU0114720955.EUR","IE00BJT1NW94.SGD","BK4534","LU1074936037.SGD","LU1670711123.USD","LU0061475181.USD","LU1670710661.SGD","LU1989771016.USD","LU0868494617.USD","LU1093756168.USD","BK4559","BK4588","BK4532","LU1093756325.SGD","IE0009355771.USD","LU0225284248.USD","IE00BSNM7G36.USD","LU2125154935.USD","LU0225771236.USD"],"gpt_icon":0},{"id":"2471387495","title":"Prime Medicine大涨约45% 与施贵宝签署研究合作与许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2471387495","media":"港股那点事","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471387495?lang=zh_cn&edition=full","pubTime":"2024-09-30 23:13","pubTimestamp":1727709180,"startTime":"0","endTime":"0","summary":"Prime Medicine (PRME.US)大涨约45%，最高触及5.02美元。消息面上，Prime Medicine与百时美施贵宝签署研究合作与许可协议，双方同意共同开发和商业化多种疗法。根据协议，施贵宝将投资5,500万美元购买Prime的股权，Prime还将获得5,500万美元的预付款，一旦完成某些销售和开发里程碑，预付款可能超过35亿美元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/bxjj/2024-09-30/doc-incqyhuh4732516.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-09-30/doc-incqyhuh4732516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0225284248.USD","LU1989771016.USD","BK4581","LU0882574055.USD","LU0306806265.USD","LU0985481810.HKD","LU0061475181.USD","LU1074936037.SGD","BK4534","IE00BSNM7G36.USD","LU0225771236.USD","LU1032466523.USD","IE00BJT1NW94.SGD","BK4007","LU1670711040.USD","LU1093756325.SGD","BK4588","BK4585","LU0306807586.USD","LU2360032135.SGD","LU0868494617.USD","IE00BFTCPJ56.SGD","LU0114720955.EUR","BMY","BK4532","LU1585245621.USD","LU1718418525.SGD","LU1670710661.SGD","IE00BJJMRZ35.SGD","LU0321505439.SGD","LU2125154778.USD","LU1571399168.USD","IE0009355771.USD","LU0321505868.SGD","LU1291159041.SGD","LU1670711123.USD","LU2242652126.USD","LU1430594728.SGD","IE0002141913.USD","LU2133065610.SGD","LU2125154935.USD","BK4559","LU0237698245.USD","LU0456855351.SGD","LU1670710588.SGD","IE00B2B36J28.USD","LU2242646821.SGD","LU1261432733.SGD","LU1093756168.USD"],"gpt_icon":0},{"id":"2471382605","title":"BUZZ-由于获得百时美施贵宝的投资和许可协议，Prime Medicine 将迎来有史以来最好的一天","url":"https://stock-news.laohu8.com/highlight/detail?id=2471382605","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471382605?lang=zh_cn&edition=full","pubTime":"2024-09-30 22:55","pubTimestamp":1727708130,"startTime":"0","endTime":"0","summary":"BUZZ-由于获得百时美施贵宝的投资和许可协议，Prime Medicine 将迎来有史以来最好的一天更新9月30日 - ** Prime Medicine PRME.O股价大涨31.5%至4.55美元，如果涨势得以保持，将创下历史最好水平。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240930:nL4S3LC1AQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","IE00BJT1NW94.SGD","BK4007","IE0002141913.USD","LU1074936037.SGD","LU1670710661.SGD","IE0009355771.USD","LU1291159041.SGD","LU2242652126.USD","LU0114720955.EUR","LU0225284248.USD","IE00BFTCPJ56.SGD","LU1670711040.USD","LU1093756325.SGD","LU1718418525.SGD","LU0061475181.USD","LU2125154935.USD","LU2360032135.SGD","LU0321505439.SGD","LU0456855351.SGD","IE00B2B36J28.USD","LU1571399168.USD","BK4532","LU1585245621.USD","BK4139","LU2125154778.USD","LU2133065610.SGD","LU1430594728.SGD","IE00BSNM7G36.USD","LU1670710588.SGD","LU0985481810.HKD","LU1670711123.USD","LU2242646821.SGD","PRME","LU0321505868.SGD","BK4581","LU0882574055.USD","LU0225771236.USD","BMY","LU1989771016.USD","LU0306806265.USD","LU1032466523.USD","LU0868494617.USD","LU1093756168.USD","LU0237698245.USD","BK4585","BK4534","LU1261432733.SGD","IE00BJJMRZ35.SGD","BK4588"],"gpt_icon":0},{"id":"2471805062","title":"BUZZ-在获得百时美施贵宝投资和达成许可协议后，Prime Medicine 公司业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2471805062","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471805062?lang=zh_cn&edition=full","pubTime":"2024-09-30 19:29","pubTimestamp":1727695784,"startTime":"0","endTime":"0","summary":" 9月30日 - ** Prime Medicine 股价在盘前大幅上涨14.7%至3.93美元** 该公司称， ，它与百时美施贵宝 签署了一项研究合作与许可协议，该制药商将向PRME的股权投资5500万美元。** PRME 表示，它还将获得 5,500 万美元的预付款，一旦完成某些销售和开发里程碑，预付款可能超过 35 亿美元。** 开发和商业化多种疗法的协议** 合作将 PRME 的基因编辑能力与 BMY 在新型细胞疗法的开发和商业化方面的专长相结合--PRME 表示 ** 截至上一交易日收盘，PRME 的股价年累计下跌约 61","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU1585245621.USD","PRME","LU1093756325.SGD","LU1670710661.SGD","LU0868494617.USD","LU1571399168.USD","LU1074936037.SGD","BK4585","LU2125154778.USD","LU0306807586.USD","LU0114720955.EUR","BMY","LU2133065610.SGD","BK4532","IE0002141913.USD","LU0306806265.USD","IE00BJT1NW94.SGD","LU1291159041.SGD","LU0321505868.SGD","BK4139","IE00BSNM7G36.USD","BK4534","LU1718418525.SGD","LU0237698245.USD","LU1989771016.USD","LU1430594728.SGD","LU1032466523.USD","BK4559","LU2125154935.USD","LU2360032135.SGD","LU0061475181.USD","BK4007","LU1261432733.SGD","IE00BFTCPJ56.SGD","LU0456855351.SGD","LU1093756168.USD","LU1670710588.SGD","BK4588","LU0321505439.SGD","LU1670711123.USD","LU0985481810.HKD","IE00B2B36J28.USD","LU0225284248.USD","LU2242646821.SGD","BK4581","LU2242652126.USD","IE0009355771.USD","LU0225771236.USD","LU0882574055.USD"],"gpt_icon":0},{"id":"2471165852","title":"百利天恒BL-B01D1获临床研究新进展 合作方百时美施贵宝积极推进产品全球临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2471165852","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471165852?lang=zh_cn&edition=full","pubTime":"2024-09-29 23:47","pubTimestamp":1727624852,"startTime":"0","endTime":"0","summary":"9月27日盘后，百利天恒（SH688506，股价163.10元，市值654.03亿元）公告，合作方百时美施贵宝（以下简称BMS）获得美国食品药品监督管理局（以下简称FDA）通知，BL-B01D1联合用药项目用于治疗晚期实体瘤的1/2a期临床试验申请已获得FDA许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202409293194499459.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202409293194499459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BL","LU0061475181.USD","BK4532","LU1670710588.SGD","LU0321505868.SGD","BK4559","IE00B2B36J28.USD","IE0002141913.USD","LU1585245621.USD","LU2360032135.SGD","LU1291159041.SGD","LU0882574055.USD","LU0868494617.USD","LU1093756168.USD","LU0225771236.USD","LU0114720955.EUR","LU1261432733.SGD","IE0009355771.USD","LU2242646821.SGD","BK4023","LU1571399168.USD","LU0306807586.USD","LU1670711123.USD","LU1032466523.USD","BK4007","IE00BJJMRZ35.SGD","LU0456855351.SGD","LU0306806265.USD","IE00BFTCPJ56.SGD","LU1815336091.USD","BMY","LU0321505439.SGD","LU1670710661.SGD","LU1670711040.USD","LU1989771016.USD","BK4588","BK4581","LU2133065610.SGD","LU2242652126.USD","LU1074936037.SGD","IE00BSNM7G36.USD","LU1093756325.SGD","LU0237698245.USD","LU0225284248.USD","LU0985481810.HKD","IE00BJT1NW94.SGD","LU2125154935.USD","LU2125154778.USD","LU0757428866.USD","BK4534"],"gpt_icon":0},{"id":"2470535270","title":"美国股票-通胀报告温和提振小型股，道指创下历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2470535270","media":"Reuters","labels":["Economic Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470535270?lang=zh_cn&edition=full","pubTime":"2024-09-28 02:56","pubTimestamp":1727463418,"startTime":"0","endTime":"0","summary":"美国商务部 报告称，消费者支出温和增长，而 通胀压力 ，继续缓解。价格降温压力促使 美联储上周降息 50 个基点。纽约证交所共创下 519 个新高和 24 个新低。标准普尔 500 指数创下 40 个 52 周新高，没有新低；纳斯达克综合指数创下 70 个新高，59 个新低。","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Economic Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DJX","IBIT","BK1575","09999","BK4139","2NVD.UK","BK4579","CVX","LU0196878994.USD","BK4526","DDM","BK4524","TQQQ",".SPX","QID","PSQ","BHP.AU","LU0164865239.USD","PDD","IWM","NQmain","BABA","L","ALTM","LU1929549753.HKD","LU0070302665.USD","LU1162221912.USD","LU1571399168.USD","AMGN",".DJI","QLD","SQQQ","89988","UDOW","BK4527","COST","BK4592","BMY","IE00BD6J9T35.USD","3NVD.UK","DXD","DOG","IE00BZ199S13.USD","SDOW","MNQmain","LU0128522744.USD","09988","NTES","BK4581",".IXIC"],"gpt_icon":1},{"id":"2470818270","title":"精神分裂新疗法药物获批，美国”医药巨头“百时美施贵宝涨1.6%！","url":"https://stock-news.laohu8.com/highlight/detail?id=2470818270","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470818270?lang=zh_cn&edition=full","pubTime":"2024-09-27 21:56","pubTimestamp":1727445412,"startTime":"0","endTime":"0","summary":"市场预计，Cobenfy 2028年销售额可达28亿美元，峰值销售额将达到约60亿美元。","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/db6aa1cd-5b84-4b5d-9bf2-142177886286.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/db6aa1cd-5b84-4b5d-9bf2-142177886286.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3729171","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3729171","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["BK1574","LU0306807586.USD","IE00BJT1NW94.SGD","BK4007","IE0002141913.USD","LU1074936037.SGD","LU1670710661.SGD","BK1161","IE0009355771.USD","LU1291159041.SGD","LU2242652126.USD","LU0114720955.EUR","LU0225284248.USD","LU1670711040.USD","LU1093756325.SGD","LU1718418525.SGD","LU2125154935.USD","LU2360032135.SGD","LU0321505439.SGD","LU0456855351.SGD","IE00B2B36J28.USD","LU1571399168.USD","BK4532","LU1585245621.USD","LU2125154778.USD","LU2133065610.SGD","LU1430594728.SGD","IE00BSNM7G36.USD","LU1670710588.SGD","LU0985481810.HKD","LU1670711123.USD","LU2242646821.SGD","LU0321505868.SGD","BK4581","LU0882574055.USD","LU0225771236.USD","BMY","LU1989771016.USD","LU0306806265.USD","BK4559","LU1032466523.USD","09939","LU0868494617.USD","LU0237698245.USD","BK4585","BK4534","LU1261432733.SGD","IE00BJJMRZ35.SGD","BK4588","BK1515"],"gpt_icon":0},{"id":"2470856190","title":"BUZZ--美国股票走势-木薯科学公司、波浪生命科学公司、班布尔公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2470856190","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470856190?lang=zh_cn&edition=full","pubTime":"2024-09-27 21:25","pubTimestamp":1727443525,"startTime":"0","endTime":"0","summary":"美东时间9:06，道指电子盘 上涨0.15%，报42,618 点。标普500指数 上涨0.16%，报5813.5点；纳斯达克100指数 上涨0.19%，报20384点。纽约证交所盘前涨幅前两位的股票 ：** Nine Energy Service, Inc ，上涨12.5%** IonQ, Inc ，上涨10.8%纽交所盘前跌幅前三名 ：** Methode Electronics, Inc ，下跌6.9%** MeridianLink, Inc ，下跌6%** OneConnect Financial Technology ，下跌6.2%纳斯达克盘前涨幅前两位的股票 ：** Onconetix, Inc ，上涨87.2%** CN Energy Group Inc ，上涨77. 6%** Bristol Myers Squibb Co ：盘前上涨 3.6%BUZZ - 因 FDA 批准其精神分裂症药物而上涨 ** 阿里巴巴集团 盘前上涨1.1%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WVE","FDN","HD","BK4503","COST","LU2095319765.USD","CPB","BK4585","BK4579","BMBL","LU2210149790.SGD","BMY","BK4509","DG","PGY","LU0823038988.USD","IE0034235188.USD","LU0314104364.USD","L","IONQ","KMX","ESTA","LOW","LU0327786744.USD","SAVA","LU0823039010.USD","LU1496350502.SGD","LU1316542783.SGD","LU0149725797.USD","LU1162221912.USD","LU0642271901.SGD","BK4501","LU1064131342.USD","LU0047713382.USD","BK4588","LU0328353924.USD","LU1674673428.USD","LU1674673691.USD","LU2210150020.SGD","CRM","LU0187121727.USD","LU2360106947.USD","AGIO","LU1046421795.USD","LU0225284248.USD","BK4581","LU1803068979.SGD","IE0009355771.USD"],"gpt_icon":1},{"id":"2470708827","title":"百时美施贵宝(BMY.US)重磅抗精神病药物获批 带动股价盘前大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2470708827","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470708827?lang=zh_cn&edition=full","pubTime":"2024-09-27 20:55","pubTimestamp":1727441738,"startTime":"0","endTime":"0","summary":"FDA周四批准了由美国医药巨头百时美施贵宝公司开发的Cobenfy(xanomeline以及trospium chloride)，作为治疗精神分裂症成人患者的最新疗法。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20240927/20240927205757_80323.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240927/20240927205757_80323.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1188456.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2133065610.SGD","LU1291159041.SGD","LU0225284248.USD","LU2242652126.USD","LU1718418525.SGD","BK4581","LU0321505439.SGD","IE00BSNM7G36.USD","IE00BFTCPJ56.SGD","BMY","LU0882574055.USD","BK4588","BK4559","LU1093756168.USD","LU1670710661.SGD","LU2242646821.SGD","LU2125154935.USD","LU0237698245.USD","LU0456855351.SGD","BK4585","LU2360032135.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU1430594728.SGD","LU1074936037.SGD","LU0225771236.USD","LU1261432733.SGD","LU0061475181.USD","LU0321505868.SGD","BK4532","BK4534","IE00BJJMRZ35.SGD","LU1670710588.SGD","LU0306806265.USD","LU0114720955.EUR","LU1670711123.USD","LU1670711040.USD","IE0002141913.USD","LU1032466523.USD","LU0868494617.USD","LU0306807586.USD","LU1571399168.USD","LU2125154778.USD","BK4007","LU1585245621.USD","LU1989771016.USD","LU1093756325.SGD","LU0985481810.HKD","IE0009355771.USD"],"gpt_icon":0},{"id":"2470707519","title":"BUZZ-券商观点布里斯托尔公司的抗精神病药物未被警告是一个重大利好消息","url":"https://stock-news.laohu8.com/highlight/detail?id=2470707519","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470707519?lang=zh_cn&edition=full","pubTime":"2024-09-27 20:18","pubTimestamp":1727439512,"startTime":"0","endTime":"0","summary":" 9月27日 - ** 美国食品和药物管理局周四晚些时候批准了 百时美施贵宝公司 的精神分裂症药物Cobenfy，使其成为几十年来第一种新型抗精神病药物。** 老年痴呆症导致的精神错乱常见于老年患者，而其他抗精神病药物会增加死亡率警告 ** 摩根大通 预计到 2025 年年中，保险公司将广泛覆盖 Cobenfy，并预计该药将获得强劲的市场份额。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","IE00BFTCPJ56.SGD","LU0985481810.HKD","LU1718418525.SGD","BK4559","BK4588","LU0061475181.USD","LU1291159041.SGD","BK4585","LU2242652126.USD","IE0009355771.USD","LU0321505868.SGD","IE00BJJMRZ35.SGD","LU0456855351.SGD","LU2360032135.SGD","LU0225284248.USD","BMY","LU2242646821.SGD","LU0225771236.USD","IE0002141913.USD","LU1032466523.USD","LU0237698245.USD","LU1571399168.USD","LU2133065610.SGD","LU0114720955.EUR","LU1989771016.USD","IE00B2B36J28.USD","LU2125154935.USD","BK4532","LU1074936037.SGD","LU0868494617.USD","LU1670710588.SGD","BK4534","LU2125154778.USD","LU0321505439.SGD","LU0882574055.USD","BK4581","LU1670710661.SGD","IE00BSNM7G36.USD","LU1585245621.USD","LU1670711040.USD","BK4007","LU1670711123.USD","LU0306807586.USD","LU1093756325.SGD","LU1261432733.SGD","IE00BJT1NW94.SGD","LU0306806265.USD","LU1093756168.USD"],"gpt_icon":0},{"id":"2470704570","title":"BUZZ--美国股票走势-Bumble、Cassava Sciences、IonQ","url":"https://stock-news.laohu8.com/highlight/detail?id=2470704570","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470704570?lang=zh_cn&edition=full","pubTime":"2024-09-27 19:46","pubTimestamp":1727437598,"startTime":"0","endTime":"0","summary":"纽约证交所盘前涨幅前三位的股票 ：** Angel Oak Mortgage REIT ，涨幅8.9%** IonQ, Inc , 涨幅8.1%** OneConnect Financial Technology ，涨幅7.8%纽交所盘前跌幅前三名 ：** Methode Electronics, Inc ，下跌6.9%** Dynatrace, Inc ，下跌6.8%** Baxter International Inc ，下跌3.7%纳斯达克盘前涨幅前两位的股票 ：** Onconetix, Inc ，上涨82.4%** CN Energy Group Inc ，上涨57.8%** Bristol Myers Squibb Co ：盘前上涨 4.4%BUZZ - 因 FDA 批准其精神分裂症药物而上涨 ** 阿里巴巴集团 盘前上涨0.4%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2264538146.SGD","LU2430703178.SGD","L","LU0310799852.SGD","LU0471298694.HKD","WVE","LU0329678337.USD","KMX","LU2361044949.HKD","DG","LU2242652126.USD","LU2592432038.USD","LI","LU0455707207.USD","LU2505996509.AUD","LU0237698245.USD","LU1093756325.SGD","LU1823568750.SGD","LU0650527681.SGD","LU1551013425.SGD","LU2461242641.AUD","COST","BMBL","LU0149725797.USD","IONQ","BABA","LU0225771236.USD","ESTA","IE000M9KFDE8.USD","HK0000320264.USD","LU0528227936.USD","LU1804176565.USD","LU0211327993.USD","LU0114720955.EUR","HK0000320223.HKD","IE00B3M56506.USD","LU0079474960.USD","LU0648001328.SGD","BMY","LU1496350171.SGD","JD","PDD","LU2430703251.USD","LU0385154629.USD","LU2505996681.GBP","SAVA","LU0605514214.HKD","LU0882574055.USD","LU2361044865.SGD","LU2361045086.USD","LU0127658192.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.bms.com","stockEarnings":[{"period":"1week","weight":0.0195},{"period":"1month","weight":0.07},{"period":"3month","weight":0.2481},{"period":"6month","weight":0.0877},{"period":"1year","weight":-0.0577},{"period":"ytd","weight":0.0372}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0413},{"period":"3month","weight":0.0648},{"period":"6month","weight":0.1806},{"period":"1year","weight":0.3709},{"period":"ytd","weight":0.2299}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"百时美施贵宝公司于1933年8月根据特拉华州法律注册成立，名为百时美公司，继承了1887年在纽约成立的一家企业。1989年，由于合并，公司更名为百时美施贵宝公司。公司在全球范围内从事生物制药产品的发现、开发、许可、制造、营销、分销和销售。他们在全球范围内从事生物制药产品的发现、开发、许可、制造、营销、分销和销售。 他们预计他们对Celgene和MyoKardia的收购将进一步将他们定位为领先的生物制药公司，通过多项近期资产和额外的外部合作伙伴扩大他们的肿瘤学、血液学、免疫学和心血管产品组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.013265},{"month":2,"riseRate":0.545455,"avgChangeRate":0.009113},{"month":3,"riseRate":0.636364,"avgChangeRate":0.008429},{"month":4,"riseRate":0.488889,"avgChangeRate":-0.002113},{"month":5,"riseRate":0.577778,"avgChangeRate":0.003555},{"month":6,"riseRate":0.622222,"avgChangeRate":0.010543},{"month":7,"riseRate":0.422222,"avgChangeRate":-0.000341},{"month":8,"riseRate":0.511111,"avgChangeRate":-0.003031},{"month":9,"riseRate":0.533333,"avgChangeRate":0.011131},{"month":10,"riseRate":0.577778,"avgChangeRate":0.024107},{"month":11,"riseRate":0.613636,"avgChangeRate":0.020382},{"month":12,"riseRate":0.636364,"avgChangeRate":0.022108}],"exchange":"NYSE","name":"施贵宝","nameEN":"Bristol-Myers Squibb"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"施贵宝,BMY,施贵宝股票,施贵宝股票老虎,施贵宝股票老虎国际,施贵宝行情,施贵宝股票行情,施贵宝股价,施贵宝股市,施贵宝股票价格,施贵宝股票交易,施贵宝股票购买,施贵宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}